- Home
- CRDO vs ROIV Comparison
CRDO vs ROIV Comparison
Compare CRDO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDO
- ROIV
- Stock Information
- Founded
- CRDO 2008
- ROIV 2014
- Country
- CRDO Cayman Islands
- ROIV United Kingdom
- Employees
- CRDO N/A
- ROIV N/A
- Industry
- CRDO Semiconductors
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CRDO Technology
- ROIV Health Care
- Exchange
- CRDO Nasdaq
- ROIV Nasdaq
- Market Cap
- CRDO 7.3B
- ROIV 8.4B
- IPO Year
- CRDO 2022
- ROIV N/A
- Fundamental
- Price
- CRDO $50.80
- ROIV $10.64
- Analyst Decision
- CRDO Strong Buy
- ROIV Buy
- Analyst Count
- CRDO 10
- ROIV 4
- Target Price
- CRDO $68.00
- ROIV $17.50
- AVG Volume (30 Days)
- CRDO 3.3M
- ROIV 6.4M
- Earning Date
- CRDO 05-28-2025
- ROIV 05-29-2025
- Dividend Yield
- CRDO N/A
- ROIV N/A
- EPS Growth
- CRDO N/A
- ROIV N/A
- EPS
- CRDO 0.03
- ROIV N/A
- Revenue
- CRDO $327,532,000.00
- ROIV $122,585,000.00
- Revenue This Year
- CRDO $125.51
- ROIV N/A
- Revenue Next Year
- CRDO $58.55
- ROIV N/A
- P/E Ratio
- CRDO $1,685.40
- ROIV N/A
- Revenue Growth
- CRDO 99.38
- ROIV 140.04
- 52 Week Low
- CRDO $16.98
- ROIV $8.73
- 52 Week High
- CRDO $86.69
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- CRDO 62.84
- ROIV 47.30
- Support Level
- CRDO $45.65
- ROIV $11.02
- Resistance Level
- CRDO $49.44
- ROIV $11.77
- Average True Range (ATR)
- CRDO 2.38
- ROIV 0.33
- MACD
- CRDO 1.39
- ROIV -0.02
- Stochastic Oscillator
- CRDO 88.03
- ROIV 28.93
About CRDO Credo Technology Group Holding Ltd
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.